MCM
ACAD icon

MAI Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

MAI Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.43K Buy
289
+4
+1% +$96 ﹤0.01% 3381
2025
Q4 		$7.61K Buy
285
+185
+185% +$4.42K ﹤0.01% 2957
2025
Q3 		$2.13K Buy
+100
New +$2.37K ﹤0.01% 3297

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

MAI Capital Management's ACAD Position: Q1 2026 in Review

MAI Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 1.4% in Q1 2026, buying an estimated $96 and bringing the position to 289 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3381.

MAI Capital Management first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. The position peaked at $7.61K in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • MAI Capital Management held 289 shares of Acadia Pharmaceuticals worth $6.43K as of Q1 2026.
  • MAI Capital Management bought 4 Acadia Pharmaceuticals shares in Q1 2026, an estimated $96.
  • Acadia Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3381 holding.
  • MAI Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • MAI Capital Management's Acadia Pharmaceuticals position peaked at $7.61K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.